

32nd EDRN Steering Committee Meeting
September 12-14, 2017
Renaissance Hotel Seattle
Seattle, Washington

Tuesday, September 12, 2017

7:00 a.m. – 8:00 a.m. <i>Madison Foyer</i>	Sign-in and Continental Breakfast
8:00 a.m. – 8:10 a.m. <i>Salon A/B</i>	<u>Opening of Steering Committee Meeting and Approval of March, 2017 EDRN Steering Committee Meeting Minutes</u> Joshua LaBaer, M.D., Ph.D., Arizona State University/The Biodesign Institute
8:10 a.m. – 8:20 a.m. <i>Salon A/B</i>	<u>Welcome</u> Garnet Anderson, Ph.D., Senior Vice President and Director, Public Health Sciences, Fred Hutchinson Cancer Research Center
8:20 a.m. – 8:40 a.m. <i>Salon A/B</i>	<u>State of the EDRN</u> Sudhir Srivastava, Ph.D., M.P.H., National Cancer Institute
8:40 a.m. – 8:45 a.m.	Q&A
8:45 a.m. – 9:10 a.m. <i>Salon A/B</i>	<u>Deep Learning for Precision Medicine</u> Hoifung Poon, Ph.D., Microsoft Research
9:10 a.m. – 9:15 a.m.	Q&A
9:15 a.m. – 12:15 p.m. <i>Salon A/B</i>	Selected Highlights of EDRN Progress <i>Session Moderator: Jo Ann Rinaudo, Ph.D., National Cancer Institute</i> [CVCs will report on their validation projects.]
9:15 a.m. – 9:35 a.m.	<u>Urinary RNA, Serum Biomarkers, and Prostate Cancer-Specific PET Imaging: A Trifecta to Enhance Prostate Cancer Detection</u> Martin Sanda, M.D., Emory University
9:35 a.m. – 9:55 a.m.	<u>Validation of Colon Cancer Biomarkers</u> Dean Brenner, M.D., University of Michigan
9:55 a.m. – 10:15 a.m.	Break

32nd EDRN Steering Committee Meeting
September 12-14, 2017
Renaissance Hotel Seattle
Seattle, Washington

Tuesday, September 12, 2017 (Continued)

Selected Highlights of EDRN Progress (Continued)

- | | |
|---|---|
| <i>10:15 a.m. – 10:35 a.m.</i>
<i>Salon A/B</i> | <u>Mucins and their Associated Serological Panel for Diagnosis of Pancreatic Cancer</u>
Randall Brand, M.D., University of Pittsburgh and
Surinder Batra, Ph.D., University of Nebraska
Medical Center |
| <i>10:35 a.m. – 10:55 a.m.</i> | <u>Biomarkers for Pancreatic Cancer Early Detection</u>
Anirban Maitra, M.B.B.S., The University of Texas
MD Anderson Cancer Center |
| <i>10:55 a.m. – 11:15 a.m.</i> | <u>FHCRC CVC Updates in Breast and Colon Cancer
Early Detection</u>
Christopher Li, M.D., Ph.D., Paul Lampe, Ph.D.,
and Charles Drescher, M.D., Fred Hutchinson
Cancer Research Center |
| <i>11:15 a.m. – 11:35 a.m.</i> | <u>Biomarkers for Ovarian Cancer Early Detection</u>
Robert Bast, M.D., The University of Texas MD
Anderson Cancer Center |
| <i>11:35 a.m. – 11:55 a.m.</i> | <u>Validation of Lung Cancer Biomarkers: Where the
Rubber Meets the Road</u>
Pierre Massion, M.D., Vanderbilt-Ingram Cancer
Center |
| <i>11:55 a.m. – 12:15 p.m.</i> | <u>MIBVAC: Images Aren't Pictures, They Are Data</u>
Robert Gillies, Ph.D., John Heine, Ph.D., Matthew
Schabath, Ph.D., and Jae Lee, Ph.D., H. Lee Moffitt
Cancer Center |
| 12:15 p.m. – 1:45 p.m.
<i>Off Site</i> | Lunch (On Your Own) |
| 12:15 p.m. – 1:45 p.m.
<i>East Room, 3rd Floor</i> | Executive Committee Meeting (closed) |

32nd EDRN Steering Committee Meeting
September 12-14, 2017
Renaissance Hotel Seattle
Seattle, Washington

Tuesday, September 12, 2017 (Continued)

1:45 p.m. – 3:45 p.m.

Salon A/B

Public Private Partnerships

Session Moderator: Lynn Sorbara, Ph.D., National Cancer Institute

1:45 p.m. – 1:50 p.m.

Welcome

Lynn Sorbara, Ph.D., National Cancer Institute

1:50 p.m. – 2:10 p.m.

Experiences and Insights on Partnering in Biomarker Discovery towards Clinical Translation

Gerard J. Davis, Ph.D., Abbott Diagnostics, Project Manager and Research Scientist

2:10 p.m. – 2:30 p.m.

Elucidating Cancer Mechanisms through Integrated Biology

Carolina Livi, Ph.D., Agilent Technologies, Inc., Academic Segment Manager

2:30 p.m. – 2:50 p.m.

GLNE-Clinical Genomics Collaboration

Lawrence LaPointe, Ph.D., Clinical Genomics

2:50 p.m. – 3:10 p.m.

Title TBD:

Jonathan Bibliowicz, Ph.D., Illumina, Inc., Sr. Sales Specialist, Sequencing & Data Analysis

3:10 p.m. – 3:30 p.m.

Exosomes Enable Liquid Biopsy Diagnostics with RNA, DNA and Protein

Johan Skog, Ph.D., Exosome Diagnostics, Inc., Chief Scientific Officer

3:30 p.m. – 3:45 p.m.

Panel Discussion:

- Carolina Livi, Ph.D., Agilent Technologies, Inc.
- Lawrence LaPointe, Ph.D., Clinical Genomics
- Jonathan Bibliowicz, Ph.D., Illumina, Inc.
- Johan Skog, Ph.D., Exosome Diagnostics, Inc.

3:45 p.m. – 4:05 p.m.

Madison Foyer

Break

32nd EDRN Steering Committee Meeting
September 12-14, 2017
Renaissance Hotel Seattle
Seattle, Washington

Tuesday, September 12, 2017 (Continued)

4:05 p.m. – 5:35 p.m.

Salon A/B

Biomarker Verification and Clinical Grade Assays

Session Moderator: Lynn Sorbara, Ph.D., National Cancer Institute

4:05 p.m. – 4:35 p.m.

University of Maryland Biomarker Reference Laboratory

Sanford Stass, M.D., University of Maryland School of Medicine

4:35 p.m. – 5:05 p.m.

Johns Hopkins University Biomarker Reference Laboratory

Daniel Chan, Ph.D., Johns Hopkins University

5:05 p.m. – 5:35 p.m.

Panel Discussion

- Sanford Stass, M.D., University of Maryland School of Medicine
- Daniel Chan, Ph.D., Johns Hopkins University
- Karin Rodland, Ph.D., Pacific Northwest National Laboratory
- Shiv Srivastava, Ph.D., Center for Prostate Disease Research
- Kenneth Cole, Ph.D., National Institute of Standards and Technology

5:35 p.m. – 5:40 p.m.

Salon A/B

Charge to Collaborative Groups

Sudhir Srivastava, Ph.D., M.P.H., National Cancer Institute

5:40 p.m.

Adjourn for the Day

Wednesday September 13, 2017

7:00 a.m. – 8:00 a.m.

Madison Foyer

Sign-in and Continental Breakfast

8:00 a.m. – 12:00 p.m.

Collaborative Group Meetings (By Invitation Only): Part 1

32nd EDRN Steering Committee Meeting
September 12-14, 2017
Renaissance Hotel Seattle
Seattle, Washington

Wednesday September 13, 2017 (Continued)

Collaborative Group Meetings (By Invitation Only): Part 1 (Continued)

Salon A

Breast and Gynecological Cancers

- Steven Skates, Ph.D., Massachusetts General Hospital
- Christopher Li, M.D., Ph.D., Fred Hutchinson Cancer Research Center

Salon B

Gastrointestinal Cancers

- Robert Schoen, M.D., M.P.H., University of Pittsburgh
- Anirban Maitra, M.B.B.S., The University of Texas MD Anderson Cancer Center

Salon C

Lung and Upper Aerodigestive Cancers

- Pierre Massion, M.D., Vanderbilt -Ingram Cancer Center
- Harvey Pass, M.D., New York University School of Medicine

East Room (3rd Floor)

Prostate and Urological Cancers

- Martin Sanda, M.D., Emory University
- John Semmes, Ph.D., Eastern Virginia Medical School

12:00 p.m. – 1:30 p.m.
Off-Site

Lunch (On Your Own)

12:00 p.m. – 1:30 p.m.
East Room (3rd Floor)

Scientific Workshop Planning Committee Meeting

1:30 p.m. – 3:00 p.m.
Salons A,B,C & East Room

Collaborative Group Meetings (By Invitation Only): Part 2

3:00 p.m. – 3:20 p.m.

Break

3:20 p.m. - 6:00 p.m.
Salon A/B

Showcase Presentations from Collaborative Groups:

Session Moderator: Christos Patriotis, Ph.D., National Cancer Institute

32nd EDRN Steering Committee Meeting
September 12-14, 2017
Renaissance Hotel Seattle
Seattle, Washington

Wednesday September 13, 2017 (Continued)

Showcase Presentations from Collaborative Groups (Continued)

- | | |
|--|--|
| <i>3:20 p.m. – 3:40 p.m.</i>
<i>Salon A/B</i> | <u>The Immuno-biology of Pulmonary Premalignancy</u>
Steve Dubinett, M.D., University of California, Los Angeles |
| <i>3:40 p.m. – 4:00 p.m.</i> | <u>Ten Years of Mesothelioma Biomarkers: Controversy and Evolution</u>
Harvey Pass, M.D., New York University |
| <i>4:00 p.m. – 4:20 p.m.</i> | <u>The sTRA Antigen: A New Blood and Tissue Biomarker for Pancreatic Cancer</u>
Daniel Barnett, B.S., Van Andel Research Institute |
| <i>4:20 p.m. – 4:40 p.m.</i> | <u>An Update on ctDNA as a Cancer Biomarker</u>
Robert Schoen, M.D., M.P.H., University of Pittsburgh |
| <i>4:40 p.m. – 5:00 p.m.</i> | <u>Integrated Genomic and Proteomic Biomarkers for Non-Invasive Identification of Aggressive Prostate Cancer</u>
Paul Boutros, Ph.D., Ontario Institute for Cancer Research |
| <i>5:00 p.m. – 5:20 p.m.</i> | <u>Development of Prostate Cancer Early Detection and Prognostic Biomarkers</u>
Scott Tomlins, M.D., Ph.D., University of Michigan |
| <i>5:20 p.m. – 5:40 p.m.</i> | <u>A Unique Tumor Derived Macrophage is a New Blood-based Biomarker for Cancer Screening and Diagnosis</u>
Jeff Marks, Ph.D., Duke University Medical Center
Cha-Mei Tang, Sc.D., Creatv MicroTech, Inc. |
| <i>5:40 p.m. – 6:00 p.m.</i> | <u>Identifying Candidate Breast Cancer Biomarkers in the Plasma of Xenografted Mice</u>
Amanda Paulovich, M.D., Ph.D., Fred Hutchinson Cancer Reserch Center |
| 6:00 p.m. – 7:00 p.m.
<i>Salon A/B</i> | Data Sharing and Informatics Subcommittee Meeting |

32nd EDRN Steering Committee Meeting
September 12-14, 2017
Renaissance Hotel Seattle
Seattle, Washington

Thursday September 14, 2017

7:00 a.m. – 8:00 a.m.

Madison Foyer

Sign-in and Continental Breakfast

8:00 a.m. – 9:40 a.m.

Salon A/B

Contemporary Topic: Interpreting Longitudinal Biomarker Changes for Early Detection

Session Moderator: Jacob Kagan, Ph.D., National Cancer Institute

8:00 a.m. – 8:20 a.m.

Overview

Margaret Pepe, Ph.D., Fred Hutchinson Cancer Research Center

8:20 a.m. – 8:25 a.m.

Q&A

8:25 a.m. – 8:45 a.m.

Ovarian Cancer

Steve Skates, Ph.D., Massachusetts General Hospital

8:45 a.m. – 8:50 a.m.

Q&A

8:50 a.m. – 9:10 a.m.

Prostate Cancer

Yingye Zheng, Ph.D., Fred Hutchinson Cancer Research Center

9:10 a.m. – 9:15 a.m.

Q&A

9:15 a.m. – 9:35 a.m.

Hepatocellular Carcinoma

Nabihah Tayob, Ph.D., The University of Texas MD Anderson Cancer Center

9:35 a.m. – 9:40 a.m.

Q&A

9:40 a.m. – 10:00 a.m.

Madison Foyer

Break

10:00 a.m. – 11:30 a.m.

Salon A/B

Reports from Collaborative Groups

Session Moderator: Guillermo Marquez, Ph.D., National Cancer Institute

32nd EDRN Steering Committee Meeting
September 12-14, 2017
Renaissance Hotel Seattle
Seattle, Washington

Thursday September 14, 2017 (Continued)

Reports from Collaborative Groups

- | | |
|--|---|
| <i>10:00 a.m. – 10:15 a.m.</i>
<i>Salon A/B</i> | <u>Colon and Esophageal Cancers</u>
Robert Schoen, M.D., M.P.H., University of Pittsburgh |
| <i>10:15 a.m. – 10:30 a.m.</i> | <u>Pancreatic Cancer</u>
Aniban Maitra, M.B.B.S., The University of Texas MD Anderson Cancer Center |
| <i>10:30 a.m. – 10:45 a.m.</i> | <u>Breast Cancer</u>
Christopher Li, M.D., Ph.D., Fred Hutchinson Cancer Research Center |
| <i>10:45 a.m. – 11:00 a.m.</i> | <u>Ovarian Cancer</u>
Steven Skates, Ph.D., Massachusetts General Hospital |
| <i>11:00 a.m. – 11:15 a.m.</i> | <u>Lung Cancer</u>
Pierre Massion, M.D., Vanderbilt - Ingram Cancer Center |
| <i>11:15 a.m. – 11:30 a.m.</i> | <u>Prostate Cancer</u>
Martin Sanda, M.D., Emory University |
| 11:30 a.m. – 11:40 a.m.
<i>Salon A/B</i> | Final Remarks <ul style="list-style-type: none">○ Joshua LaBaer, M.D., Ph.D., Arizona State University/The Biodesign Institute○ Sudhir Srivastava, Ph.D., M.P.H., National Cancer Institute |
| 11:40 a.m. | Adjourn |